Refractory polymyositis responding to infliximab
نویسندگان
چکیده
منابع مشابه
Refractory neurosarcoidosis responding to infliximab
Neurology Steven A. Sparr Receptive amelodia in a trained musician This information is current as of July 24, 2007 http://www.neurology.org/cgi/content/full/59/10/1659 located on the World Wide Web at: The online version of this article, along with updated information and services, is All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X. since 1951, it is now a weekly with 48 issu...
متن کاملRefractory multisystem sarcoidosis involving pelvic bone responding to infliximab
Background Chronic progressive multisystem granulomatous disease is seen in 10–30% of patients with sarcoidosis and can result in end organ damage [1]. Corticosteroids are the mainstay of treatment with the addition of cytotoxic agents in severe cases. Some patients are refractory to such treatment and therefore management is a challenge. There is currently limited evidence for biological agent...
متن کاملFatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab.
this was a coincidental occurrence or whether the etanercept caused exacerbation of an active subclinical infection. The chronic steroid therapy with 25mg of prednisone daily should also be considered as an additional contributing factor in masking the infection. In our review of the literature only two cases of fatal sepsis associated with tumour necrosis factor alpha (TNF) blockers were repor...
متن کاملInfliximab for refractory ulcerative proctitis.
BACKGROUND Efficacy of infliximab in treating ulcerative proctitis remains unknown. AIM To evaluate the clinical, biological and endoscopic efficacy of infliximab therapy in refractory proctitis. METHODS The charts of 420 patients treated with infliximab for ulcerative colitis were reviewed. Thirteen patients were treated with infliximab for refractory ulcerative proctitis in six referral c...
متن کاملInfliximab for Refractory Noninfectious Uveitis
Kruh et al. set out to establish whether infliximab is safe and effective for the treatment of refractory noninfectious uveitis. They found that the drug—a monoclonal antibody used in treating several chronic inflammatory diseases—induced a high rate of complete clinical remission in recalcitrant uveitis and was well tolerated by most patients. In this retrospective, interventional, noncomparat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2004
ISSN: 1460-2172
DOI: 10.1093/rheumatology/keh268